Diabetes Mellitus

You might also like

Download as ppt, pdf, or txt
Download as ppt, pdf, or txt
You are on page 1of 181

Nurse Licensure Examination

Review

Diabetes Mellitus
Diabetes Mellitus
 A group of metabolic diseases
characterized by elevated levels
of glucose in the blood resulting
from defects in insulin secretion,
insulin action, insulin receptors
or any combination of conditions.
Diabetes Mellitus

 A chronic disorder of impaired


glucose metabolism, protein
and fat metabolism
Diabetes Mellitus
 BASIC PATHOLOGY :
Insulin problem
(deficiency or impaired
action)
Diabetes Mellitus
 Insulin is a hormone
secreted by the BETA cells
of the pancreas
 Stimulus of insulin-
HYPERGLYCEMIA
Diabetes Mellitus
 Action of insulin: it
promotes entry of Glucose
into the body cells by
binding to the insulin
receptor in the cell
membrane
INSULIN : Physiology
Insulin Metabolic Functions:
 1. Transports and metabolizes GLUCOSE
 2. Promotes GLYCOGENESIS
 3. Promotes GLYCOLYSIS
 4. Enhances LIPOGENESIS
 5. Accelerates PROTEIN SYNTHESIS
Diabetes Mellitus
RISK FACTORS for Diabetes
Mellitus
 1. Family History of diabetes
 2. Obesity
 3. Race/Ethnicity
Diabetes Mellitus
RISK FACTORS for Diabetes
Mellitus
 4. Age of more than 45
 5. Previously unidentified
IFG/IGT
 6. Hypertension
Diabetes Mellitus
RISK FACTORS for
Diabetes Mellitus
 7. Hyperlipidemia
 8. History of Gestational
Diabetes Mellitus
Diabetes Mellitus
CLASSIFICATION OF DM
1. Type 1 DM
 Insulin dependent Diabetes Mellitus
2. Type 2 DM
 Non-insulin dependent Diabetes Mellitus
3. Gestational DM
 Diabetes Mellitus diagnosed during pregnancy
4. DM associated with other conditions or
syndromes
Diabetes Mellitus
CLASSIFICATION OF DM
1. Type 1 DM
 Insulin dependent Diabetes
Mellitus
Diabetes Mellitus
CLASSIFICATION OF DM
2. Type 2 DM
 Non-insulin dependent
Diabetes Mellitus
Diabetes Mellitus
CLASSIFICATION OF DM
3. Gestational DM
 Diabetes Mellitus diagnosed
during pregnancy
Diabetes Mellitus
CLASSIFICATION OF DM
4. DM associated with other
conditions or syndromes
Diabetes Mellitus
Other types of DM
 1. Impaired Glucose
Tolerance
 2. Impaired Fasting Glucose
 3. Pre-diabetes
TYPE 1- Diabetes Mellitus
This type of DM is
characterized by the
destruction of the
pancreatic beta cells
TYPE 1- Diabetes Mellitus
Etiology:
1. Genetic susceptibility- HLA DR3
and DR4
2. Autoimmune response
3. Toxins, unidentified viruses and
environmental factors
TYPE 1- Diabetes Mellitus
PATHOPHYSIOLOGY
 Destruction of BETA cells
decreased insulin production 
uncontrolled glucose production
by the liver hyperglycemia 
signs and symptoms
TYPE 1- Diabetes Mellitus
PATHOPHYSIOLOGY
CLASSIC P’s
 Polyuria
 Polydipsia
 Polyphagia
TYPE 2- Diabetes Mellitus
 A type of DM characterized
by insulin resistance and
impaired insulin production
TYPE 2- Diabetes Mellitus
Etiology:
1. Unknown
2. Probably genetic and
obesity
TYPE 2- Diabetes Mellitus
PATHOPHYSIOLOGY
 Decreased sensitivity of insulin
receptor to insulin  less
uptake of glucose 
HYPERGLYCEMIA
TYPE 2- Diabetes Mellitus
PATHOPHYSIOLOGY
 Decreased insulin production 
diminished insulin action 
hyperglycemia  signs and
symptoms
TYPE 2- Diabetes Mellitus
PATHOPHYSIOLOGY
 BUT (+) insulin in small
amount  prevent
breakdown of fats  DKA is
unusual
GESTATIONAL Diabetes Mellitus
 Any degree of glucose
intolerance with its onset
during pregnancy
 Usually detected between 24-
28 week gestation
th
GESTATIONAL Diabetes Mellitus
 Blood glucose returns to normal
after delivery of the infant
 NEVER administer ORAL
HYPOGLYCEMIC AGENTS to
PREGNANT MOTHERS!
Diabetes Mellitus
ASSESSMENT FINDINGS
 1. Classic 3 P’s
 2. Fatigue
 3. Body weakness
Diabetes Mellitus
ASSESSMENT FINDINGS
 4. Visual changes
 5. Slow wound healing
 6. Recurrent skin and mucus
membrane infections
Diabetes Mellitus
DIAGNOSTIC TESTS
 1. FBS- > 126
 2. RBS- >200
 3. OGTT- > 200
Diabetes Mellitus
DIAGNOSTIC TESTS
 4. HgbA1- for monitoring!!
 5. Urine glucose
 6. Urine ketones
Diabetes Mellitus
DIAGNOSTIC CRITERIA
 1. FBS equal to or greater
than 126 mg/dL (7.0mmol/L)
 (Normal 8 hour FBS- 80-
109 mg/dL)
Diabetes Mellitus
DIAGNOSTIC CRITERIA
 2. OGTT value 1 and 2 hours
post-prandial equal to or
greater than 200 mg/dL
 Normal OGTT 1 and 2 hours
post-prandial- is
 140 mg/dL
Diabetes Mellitus
DIAGNOSTIC CRITERIA
 3.RBS of equal to or
greater than 200 mg/dL
PLUS the 3 P’s
Diabetes Mellitus
NURSING MANAGEMENT OF
DM
 The main goal is to
NORMALIZE insulin activity
and blood glucose level by:
Diabetes Mellitus
NURSING MANAGEMENT OF DM
1. Nutritional modification
2. Regular Exercise
3. Regular Glucose Monitoring
4. Drug therapy
5. Client Education
Diabetes Mellitus
The Patient with DM
 HISTORY
 Symptoms and characteristics
 PHYSICAL EXAMINATION
 VS, BMI, Fundoscopy, Neuro
 LABORATORY EXAMINATION
 FBS, RBS, HgbA1c, lipid profile, ECG, UA
 REFERRALS
 Ophthalmologist, Podiatrist, Dietician, etc..
Diabetes Mellitus
The Patient with DM
 HISTORY
 Symptoms and characteristics
 PHYSICAL EXAMINATION
 VS, BMI, Fundoscopy, and
Neuro assessment
Diabetes Mellitus
The Patient with DM
 LABORATORY EXAMINATION
 FBS, RBS, HgbA1c, lipid profile,
ECG, and Urinalysis
 REFERRALS
 Ophthalmologist, Podiatrist,
Dietician, etc..
DM Nutritional management
Diabetes Mellitus
NUTRITIONAL MANAGEMENT
 1.Review the patient’s diet history
to identify eating habits and
lifestyle
 2. Coordinate with the dietician in
meal planning for weight loss
Diabetes Mellitus
NUTRITIONAL MANAGEMENT
 3. Plan for the caloric intake
distributed as follows- CHO 50-60%;
Fats 20-30%; and Proteins 10-20%
 4. Advise moderation in alcohol
intake
 5. Using artificial sweeteners is
acceptable
DM Exercise management
Diabetes Mellitus
EXERCISE Management
 1. Teach that exercise can lower
the blood glucose level
 2. Diabetics must first control
the glucose level before initiating
exercise programs.
Diabetes Mellitus
EXERCISE Management
 3. Offer extra food /calories
before engaging in exercise
 4. Offer snacks at the end of the
exercise period if patient is on
insulin treatment.
Diabetes Mellitus
EXERCISE Management
 5. Advise that exercise should be
done at the same time every day,
preferably when blood glucose
levels are at their peak
Diabetes Mellitus
EXERCISE Management
 6. Regular exercise, not sporadic
exercise, should be encouraged.
 7. For most patient, WALKING
is the safe and beneficial form of
exercise
Glucose Self Monitoring
Diabetes Mellitus
GLUCOSE MONITORING
 Self-monitoring of blood glucose
(SMBG) enables the patient to
adjust the treatment regimen to
obtain optimal glucose control
Diabetes Mellitus
GLUCOSE MONITORING
 Most common method involves
obtaining a drop of capillary
blood applied to a test strip.
 The usual recommended
frequency is TWO-FOUR times
a day.
Diabetes Mellitus
When is it done?
 At the peak action time of the
medication to evaluate the need
for adjustments.
 To evaluate BASAL insulin 
test before meals
Diabetes Mellitus
When is it done?
 To titrate bolus or regular and
lispro test 2 hours after meals.
 To evaluate the glucose level of
those taking ORAL hypoglycemics
 test before and two hours after
meals.
Diabetes Mellitus Monitoring therapy
 Testing the glycosylated
hemoglobin (HbA1c)
 This glycosylated hemoglobin
refers to the blood test that
reflects the average blood glucose
over a period of TWO to THREE
months.
Diabetes Mellitus Monitoring therapy
 Normal value is 4 to 6 %
 No patient preparation is
needed for this testing
 Done to monitor therapy
Diabetes Mellitus
 Urine testing for glucose
 Benedict’s test
Diabetes Mellitus
 Urine testing for ketones
 Ketones are by-products
of fat breakdown
Diabetes Mellitus
 Urine testing for ketones
 This is performed whenever
TYPE 1 DM have glucosuria or
persistent elevation of blood
glucose, during illness, and in
gestational diabetes
DM Drug therapy
Diabetes Mellitus
DRUG THERAPY and
MANAGEMENT
 Usually, this type of management is
employed if diet modification and
exercise cannot control the blood
glucose level.
Diabetes Mellitus
DRUG THERAPY and
MANAGEMENT
 Because the patient with TYPE
1 DM cannot produce insulin,
exogenous insulin must be
administered for life.
Diabetes Mellitus
DRUG THERAPY and
MANAGEMENT
 TYPE 2 DM may have
decreased insulin production,
ORAL agents that stimulate
insulin production are usually
employed.
Diabetes Mellitus
PHARMACOLOGIC INSULIN
 This may be grouped into several
categories according to:
1. Source- Human, pig, or cow
2. Onset of action- Rapid-acting,
short-acting, intermediate-acting,
long-acting and very long acting
Diabetes Mellitus
PHARMACOLOGIC INSULIN
 This may be grouped into several
categories according to:
3. Pure or mixed concentration
4. Manufacturer of drug
Diabetes Mellitus
GENERALITIES
 1. Human insulin preparations
have a shorter duration of action
than animal source
Diabetes Mellitus
GENERALITIES
 2. Animal sources of insulin have
animal proteins that may trigger
allergic reaction and they may
stimulate antibody production
that may bind the insulin, slowing
the action
Diabetes Mellitus
 3.
ONLY Regular insulin
can be used
INTRAVENOUSLY!
Diabetes Mellitus
 4. Insulin are measured in
INTERNATIONAL UNITS or
“iu”
 5. There is a specified insulin
injection calibrated in units
Diabetes Mellitus
RAPID ACTING INSULIN
 Lispro (Humalog) and Insulin
Aspart (Novolog)
 Produces a more rapid effect
and with a shorter duration than
any other insulin preparation
Diabetes Mellitus
RAPID ACTING INSULIN
 ONSET- 5-15 minutes
 PEAK- 1 hour
 DURATION- 3 hours
 Instruct patient to eat within 5 to 15
minutes after injection
Diabetes Mellitus
REGULAR INSULIN
 Also called Short-acting insulin
 “R”
 Usually Clear solution
administered 30 minutes before
a meal
Diabetes Mellitus
REGULAR INSULIN
 ONSET- 30 minutes to 1 hour
 PEAK- 2 to 3 hours
 DURATION- 4 to 6 hours
Diabetes Mellitus
INTERMEDIATE ACTING
INSULIN
 Called “NPH” or
“LENTE”
 Appears white and cloudy
Diabetes Mellitus
INTERMEDIATE ACTING
INSULIN
 ONSET- 2-4 hours
 PEAK- 4 to 6-12 hours
 DURATION- 16-20 hours
Diabetes Mellitus
LONG- ACTING INSULIN
 “UltraLENTE”
 Referred to as “peakless”
insulin
Diabetes Mellitus
LONG- ACTING INSULIN
 ONSET- 6-8 hours
 PEAK- 12-16 hours
 DURATION- 20-30 hours
Diabetes Mellitus
HEALTH TEACHING
Regarding Insulin SELF-
Administration
 1. Insulin is administered at
home subcutaneously
Diabetes Mellitus
HEALTH TEACHING Regarding
Insulin SELF- Administration
 2. Cloudy insulin should be
thoroughly mixed by gently
inverting the vial or ROLLING
between the hands
Diabetes Mellitus
HEALTH TEACHING Regarding
Insulin SELF- Administration
 3. Insulin NOT IN USE should be
stored in the refrigerator, BUT
avoid freezing/extreme
temperature
Diabetes Mellitus
 4. Insulin IN USE should be
kept at room temperature to
reduce local irritation at the
injection site
Diabetes Mellitus

 5. INSULIN may be kept at


room temperature up to 1
month
Diabetes Mellitus
 6. Select syringes that match
the insulin concentration.
 U-100 means 100 units per
mL
Diabetes Mellitus
 7.
Instruct the client to draw
up the REGULAR (clear)
Insulin FIRST before
drawing the intermediate
acting (cloudy) insulin
Diabetes Mellitus
 8. Pre-filled syringes can be
prepared and should be kept
in the refrigerator with the
needle in the UPRIGHT
position to avoid clogging the
needle
Diabetes Mellitus
 9. The four main areas for
insulin injection are-
ABDOMEN, UPPER ARMS,
THIGHS and HIPS
Diabetes Mellitus
 Insulin is absorbed fastest in the
abdomen and slowest in the hips
 Instruct the client to rotate the areas
of injection, but exhaust all available
sites in one area first before moving
into another area.
Diabetes Mellitus
 10. Alcohol may not be used to
cleanse the skin
 11. Utilize the subcutaneous
injection technique-
commonly, a 45-90 degree
angle.
Diabetes Mellitus
 12. No need to instruct for
aspirating the needle
 13. Properly discard the
syringe after use.
Diabetes Mellitus
T-I-E
Test blood Inject insulin  Eat
food
Diabetes Mellitus
COMPLICATIONS OF INSULIN
THERAPY
1. Local allergic reactions
 Redness, swelling, tenderness and
induration appearing 1-2 hours
after injection
 Usually occurs in the beginning
stage of therapy
Diabetes Mellitus
COMPLICATIONS OF INSULIN THERAPY
1. Local allergic reactions
 Disappears with continued use
 Antihistamine can be given 1 hour
before injection time
 Porcine and bovine insulin
preparations have a higher
tendency to produce this reaction.
Diabetes Mellitus
2. SYSTEMIC ALLERGIC
REACTIONS
 Very rare
 Generalized urticaria is the
manifestation
 Treatment is desensitization
Diabetes Mellitus

COMPLICATIONS OF INSULIN
THERAPY
3. INSULIN DYSTROPHY
 A localized reaction in the form
of lipoatrophy or lipohypertrophy
Diabetes Mellitus

 Lipoatrophy- loss of
subcutaneous fat usually
caused by the utilization of
animal insulin
Diabetes Mellitus
 Lipohypertrophy-
development of fibrofatty
masses, usually caused by
repeated use of injection site
Diabetes Mellitus
4. INSULIN RESISTANCE
 Most commonly caused by
OBESITY
 Defined as daily insulin requirement
of more than 200 units
 Management- Steroids and use of
more concentrated insulin
Diabetes Mellitus
5. MORNING HYPERGLYCEMIA
 Elevated blood sugar upon arising in
the morning
 Caused by insufficient level of insulin
 DAWN phenomenon
 SOMOGYI effect
 INSULIN WANING
Diabetes Mellitus
DAWN PHENOMENON
 Relatively normal blood glucose until
about 3 am, when the glucose level
begins to RISE
 Results from the nightly surges of
GROWTH HORMONE secretion
 Management: Bedtime injection of
NPH
Diabetes Mellitus
SOMOGYI EFFECT
 Normal or elevated blood
glucose at bedtime, decrease
blood glucose at 2-3 am due to
hypoglycemic levels and a
subsequent increase in blood
glucose (rebound hypergycemia)
Diabetes Mellitus
SOMOGYI EFFECT
 Nocturnal hypoglycemia
followed by rebound
hyperglycemia
Diabetes Mellitus
SOMOGYI EFFECT
 Due to the production of
counter regulatory
hormones- glucagon. cortisol
and epinephrine
 Management- decrease
evening dose of NPH or
increase bedtime snack
Diabetes Mellitus
INSULIN WANING
 Progressive rise in blood glucose
from bedtime to morning
 Seen when the NPH evening dose
is administered before dinner
 Management: Move the insulin
injection to bedtime
Diabetes Mellitus
ORAL HYPOGLYCEMIC
AGENTS
 These may be effective when
used in TYPE 2 DM that cannot
be treated with diet and exercise
 These are NEVER used in
pregnancy!
Diabetes Mellitus
ORAL HYPOGLYCEMIC AGENTS
 There are several agents:
 Sulfonylureas
 Biguanides
 Alpha-glucosidase inhibitors
 Thiazolidinediones
 Meglitinides
Diabetes Mellitus
SULFONYLUREAS
 MOA- stimulates the beta
cells of the pancreas to
secrete insulin
 Classified as to generations-
first and second generations
Diabetes Mellitus
SULFONYLUREAS
 FIRST GENERATION-
Acetoheximide, Chlorpropamide,
Tolazamide and Tolbutamide
 SECOND GENERATION- Glipizide,
Glyburide, Glibenclamide,
Glimepiride
Diabetes Mellitus: Sulfonylureas
 The most common side –effects
of these medications are Gastro-
intestinal upset and
dermatologic reactions.
 HYPOGLYCEMIA is also a
very important side-effect
Diabetes Mellitus: Sulfonylureas
 Chlorpropamide has a very long
duration of action. This also
produces a disulfiram-like reaction
when taken with alcohol
 Second generation drugs have
shorter duration with metabolism in
the kidney and liver and are the
choice for elderly patients
Diabetes Mellitus
BIGUANIDES
 MOA- Facilitate the action of
insulin on the peripheral
receptors
 These can only be used in the
presence of insulin
Diabetes Mellitus
BIGUANIDES= “formin”
 They have no effect on the
beta cells of the pancreas
 Metformin (Glucophage) and
Phenformin are examples
Diabetes Mellitus: Biguanides
 The most important side effect
is LACTIC ACIDOSIS!
 These are not given to patient
with renal impairment
Diabetes Mellitus: Biguanides

 These drugs are usually given


with a sulfonylurea to enhance
the glucose-lowering effect
more than the use of each drug
individually
Diabetes Mellitus
ALPHA-GLUCOSIDASE INHIBITORS
 MOA- Delay the absorption of glucose in the
GIT
 Result is a lower post-prandial blood glucose
level
 They do not affect insulin secretion or
action!
 Side-effect: DIARRHEA and
FLATULENCE
Diabetes Mellitus
 Examples of AGI are Acarbose
and Miglitol
 They are not absorbed
systemically and are very safe
 They can be used alone or in
combination with other OHA
Diabetes Mellitus
 Side-effect if used with other
drug is HYPOGLYCEMIA
 Note that sucrose absorption is
impaired and IV glucose is the
therapy for the hypoglycemia
Diabetes Mellitus
THIAZOLIDINEDIONES
 MOA- Enhance insulin
action at the receptor site
 They do not stimulate insulin
secretion
Diabetes Mellitus
THIAZOLIDINEDIONES
 Examples- Rosiglitazone, Pioglitazone
 These drugs affect LIVER
FUNCTION
 Can cause resumption of
OVULATION in peri-menopausal
anovulatory women
Diabetes Mellitus
MEGLITINIDES
 MOA- Stimulate the
secretion of insulin by the
beta cells
 Examples- Repaglinide and
Nateglinide
Diabetes Mellitus
MEGLITINIDES
 They have a shorter duration
and fast action
 Should be taken BEFORE meals
to stimulate the release of insulin
from the pancreas
Diabetes Mellitus
MEGLITINIDES
 Principal side-effect of
meglitinides- hypoglycemia
 Can be used alone or in
combination
Diabetes Mellitus
ACUTE COMPLICATIONS OF DM
 Hypoglycemia
 Diabetic ketoacidosis
 Hyperglycemic hyperosmolar non-
ketotic syndrome (HHNS)
Diabetes Mellitus
CHRONIC COMPLICATIONS OF DM
 Macrovascular complications- MI,
Stroke, Atherosclerosis, CAD, and
Peripheral vascular disease
 Microvascular complications- micro-
angiopathy, retinopathy, nephropathy
 Peripheral neuropathy
Diabetes Mellitus
HYPOGLYCEMIA
 Blood glucose level less than 50 to 60
mg/dL
 Causes: Too much insulin/OHA, too
little food and excessive physical
activity
 Mild- 40-60
 Moderate- 20-40
 Severe- less than 20
HYPOGLYCEMIA
ASSESSMENT FINDINGS
 1. Sympathetic manifestations-
sweating, tremors, palpitations,
nervousness, tachycardia and
hunger
HYPOGLYCEMIA
ASSESSMENT FINDINGS
 2. CNS manifestations- inability to
concentrate, headache,
lightheadedness, confusion, memory
lapses, slurred speech, impaired
coordination, behavioral changes,
double vision and drowsiness
HYPERGLYCEMIA
HYPOGLYCEMIA
 DIAGNOSTIC FINDINGS
 RBS- less than 50-60 mg/dL
level
HYPOGLYCEMIA
Nursing Interventions
 1. Immediate treatment with the
use of foods with simple sugar-
glucose tablets, fruit juice, table
sugar, honey or hard candies
HYPOGLYCEMIA
Nursing Interventions
 2. For uncons cio us
patient s- glucagon injection 1
mg IM/SQ; or IV 25 to 50 mL of
D50/50
HYPOGLYCEMIA
Nursing Interventions
 3. re-test glucose level in 15
minutes and re-treat if less than
75 mg/dL
 4. Teach patient to refrain from
eating high-calorie, high-fat
desserts
HYPOGLYCEMIA
Nursing Interventions
 5. Advise in-between snacks,
especially when physical activity
is increased
 6. Teach the importance of
compliance to medications
Diabetic Ketoacidosis
 This is cause by the absence of insulin
leading to fat breakdown and production
of ketone bodies
 Three main clinical features:
 1. HYPERGLYCEMIA
 2. DEHYDRATION & electrolyte loss
 3. ACIDOSIS
DKA
PATHOPHYSIOLOGY
 No insulin reduced glucose
breakdown and increased liver
glucose production 
Hyperglycemia
DKA
PATHOPHYSIOLOGY
 Hyperglycemia kidney
attempts to excrete glucose 
increased osmotic load 
diuresis  Dehydration
DKA
PATHOPHYSIOLOGY
 No glucose in the cell fat is
broken down for energy 
ketone bodies are produced
Ketoacidosis
DKA
Risk factors
 1. infection or illness- common
 2. stress
 3. undiagnosed DM
 4. inadequate insulin, missed dose
of insulin
DKA
ASSESSMENT FINDINGS
 1. 3 P’s
 2. Headache, blurred vision and
weakness
 3. Orthostatic hypotension
DKA
ASSESSMENT FINDINGS
 4. Nausea, vomiting and
abdominal pain
 5. Acetone (fruity) breath
 6. Hyperventilation or
KUSSMAUL’s breathing
HYPERGLYCEMIA
Hyperglycemia
DKA
LABORATORY FINDINGS
 1. Blood glucose level of 300-
800 mg/dL
 2. Urinary ketones
DKA
LABORATORY FINDINGS
 3. ABG result of metabolic acidosis-
LOW pH, LOW pCO2 as a
compensation, LOW bicarbonate
 4. Electrolyte imbalances- potassium
levels may be HIGH due to acidosis
and dehydration
DKA
NURSING INTERVENTIONS
 1. Assist in the correction of
dehydration
 Up to 6 liters of fluid may be ordered
for infusion, initially NSS then D5W
 Monitor hydration status
 Monitor I and O
 Monitor for volume overload
DKA
NURSING INTERVENTIONS
 2. Assist in restoring Electrolytes
 Kidney function is FIRST
determined before giving
potassium supplements!
DKA
NURSING INTERVENTIONS
 3. Reverse the Acidosis
 REGULAR insulin injection is
ordered IV bolus 5-10 units
 The insulin is followed by drip
infusion in units per hour
 BICARBONATE is not used!
HHNS
 A serious condition in which
hyperosmolarity and extreme
hyperglycemia predominate
 Ketosis is minimal
 Onset is slow and takes hours to
days to develop
HHNS
PATHOPHYSIOLOGY
 Lack of insulin action or Insulin
resistance  hyperglycemia
 Hyperglycemia osmotic
diuresis  loss of water and
electrolytes
HHNS
PATHOPHYSIOLOGY
 Insulin is too low to prevent
hyperglycemia but enough to
prevent fat breakdown
 Occurs most commonly in type 2
DM, ages 50-70
HHNS
Precipitating factors
 1. Infection
 2. Stress
 3. Surgery
 4. Medication like thiazides
 5. Treatment like dialysis
HHNS
ASSESSMENT FINDINGS
 1. Profound dehydration
 2. Hypotension
 3. Tachycardia
 4. Altered sensorium
 5. Seizures and hemiparesis
HHNS
DIAGNOSTIC TESTS
 1. Blood glucose- 600 to 1,200
mg/dL
 2. Blood osmolality- 350
mOsm/L
 3. Electrolyte abnormalities
HHNS
NURSING INTERVENTIONS
 Approach is similar to the DKA
 1. Correction of Dehydration by
IVF
 2. Correction of electrolyte
imbalance by replacement
therapy
HHNS
NURSING INTERVENTIONS
 3. Administration of insulin
injection and drips
 4. Continuous monitoring of
urine output
MACROVASCULAR CX
Nursing management
 1. Diet modification
 2. Exercise
MACROVASCULAR CX
Nursing management
 3. Prevention and treatment of
underlying conditions such as
MI, CAD and stroke
 4. Administration of prescribed
medications for hypertension,
hyperlipidemia and obesity
MICROVASCULAR CX
 Retinopathy- a painless deterioration
of the small blood vessels in the retina,
may be classified as to background
retinopathy, pre-proliferative and
proliferative retinopathy
 Permanent vision changes and
blindness can occur
MICROVASCULAR CX
Retinopathy-ASSESSMENT
FINDINGS
 Blurry vision
 Spotty vision
 Asymptomatic
MICROVASCULAR CX
Retinopathy: Diagnostic findings
 1. Fundoscopy
 2. Fluorescein angiography
 Painless procedure
 Side-effects- discoloration of the skin
and urine for 12 hours, some allergic
reactions, nausea
 Flash of camera may be slightly
uncomfortable
MICROVASCULAR CX
NURSING INTERVENTIONS
 1. Assist in diagnostic procedure
 2. Assist in the preparation for
surgery- laser photocoagulation
MICROVASCULAR CX
NURSING INTERVENTIONS
 3. Health teaching regarding
prevention of retinopathy by
regular ophthalmic examinations,
good glucose control and self-
management of eye care regimens
 4. Maintain client safety
MICROVASCULAR CX
DIABETIC NEPHROPATHY
 Progressive deterioration of
kidney function
MICROVASCULAR CX
DIABETIC NEPHROPATHY
 HYPERGLYCEMIA causes the
kidney filtration mechanism to be
stressed  blood proteins leak into
the urine
 Pressure in the kidney blood vessels
increases stimulate the development
of nephropathy
MICROVASCULAR CX
ASSESSMENT findings for diabetic
nephropathy
 1. Albuminuria
 2. Anemia
 3. Acidosis
MICROVASCULAR CX
ASSESSMENT findings for diabetic
nephropathy
 4. Fluid volume overload
 5. Oliguria
 6. Hypertension
 7. UTI
MICROVASCULAR CX
NURSING MANAGEMENT
1. Assist in the control of
hypertension- use of ACE inhibitor
2. Provide a low sodium and low
protein diet
3. Administer prescribed medication
for UTI
MICROVASCULAR CX
 NURSING MANAGEMENT
4. Assist in dialysis
5. Prepare patient for renal
transplantation, if indicated
MICROVASCULAR CX
Diabetic Neuropathy
 A group of disorders that affect
all type of nerves including the
peripheral, autonomic and
spinal nerves
MICROVASCULAR CX
Diabetic Neuropathy
 Two most common types of
Diabetic Neuropathy are
sensori-motor polyneuropathy
and autonomic neuropathy
MICROVASCULAR CX
Peripheral neuropathy-
ASSESSMENT findings
 1. paresthesias- prickling, tingling
or heightened sensation
 2. decreased proprioception
 3. decreased sensation of light touch
 4. unsteady gait
 5. decreased tendon reflexes
MICROVASCULAR CX
Peripheral neuropathy- Nursing
Management
 1. Provide teaching that good glucose
control is very important to prevent
its development
 2. Manage the pain by analgesics,
antidepressants and nerve
stimulation
MICROVASCULAR CX
Autonomic Neuropathy- ASSESSMENT
findings
 1. Silent, painless ischemia
 2. delayed gastric emptying
 3. orthostatic hypotension
 4. N/V and bloating sensation
 5. urinary retention
 6. sexual dysfunction
MICROVASCULAR CX
Autonomic Neuropathy-Nursing
management
 1. Educate about the avoidance of
strenuous physical activity
 2. Stress the importance of good
glucose control to delay the
development
MICROVASCULAR CX
Autonomic Neuropathy-Nursing
management
 3. Provide LOW-fat, small frequent
feedings
 4. Administer bulk-forming
laxatives for diabetic diarrhea
 5. Provide HIGH-fiber diet for
diabetic constipation
MICROVASCULAR CX
MANAGEMENT OF FOOT AND LEG
PROBLEMS

 Soft tissue injury in the foot/leg


formation of fissures and callus 
poor wound healing  foot/leg ulcer
MICROVASCULAR CX
RISK FACTORS for the development of
foot and leg ulcers
 1. More than 10 years diabetic
 2. Age of more than 40
 3. Smoking
 4. Anatomic deformities
 5. History of previous leg ulcers or
amputation
MICROVASCULAR CX
MANAGEMENT of Foot Ulcers
 Teach patient proper care of the
foot
 Daily assessment of the foot
 Use of mirror to inspect the
bottom
MICROVASCULAR CX
MANAGEMENT of Foot Ulcers
 Inspect the surface of shoes for
any rough spots or foreign objects
 Properly dry the feet
 Instruct to wear closed-toe shoes
that fit well, recommend use of
low-heeled shoes
MICROVASCULAR CX
MANAGEMENT
 Instruct patient NEVER to walk
barefoot, never to use heating pads,
open-toed shoes and soaking feet
 Trim toenails STRAIGHT ACROSS and
file sharp corners
 Instruct to avoid smoking and over-the
counter medications and home remedies
for foot problems

You might also like